The REPAIR-AMI and ASTAMI trials: cell isolation procedures.

10 The time between myocar-dial infarction and intracoronary infusion therapy was nearly identical in the BMC and placebo group (median of 4 days), thus any spontaneous improvement in left ventri-cular ejection fraction (LVEF) prior to intra-coronary infusion therapy may have occurred to the same extent in both groups. As suggested by Marenzi and Bartor-elli, we re-analysed a potential effect of time to reperfusion therapy and infarct location on treatment effect by BMC administration. Randomization to BMC remained significantly associated with improved recovery of LVEF after adjusting for time to first reperfusion therapy (P ¼ 0.013) as well as infarct location (anterior vs. inferior) (P ¼ 0.021). There was no interaction between BMC treatment effect and infarct location (P ¼ 0.87) or time to reperfusion (P ¼ 0.60). Likewise, the beneficial effect of BMC administration on the combined clinical end point death, recurrent myocardial infarction, or revascularization procedures remained statistically significant in favour of BMC therapy, when adjusting for time to reperfusion therapy (P ¼ 0.018) or infarct location (P ¼ 0.013). Neither infarct location (P ¼ 0.37) nor time to reperfusion (categorized according to the median of 4.5 h) (P ¼ 0.47) was predictive for cardiovascular event rate. Thus, neither infarct location nor time to reperfusion had an impact on the results of the REPAIR-AMI trial, that intra-coronary BMC administration favourably affects recovery of LVEF as well as clinical outcome. References 1. Osterziel KJ. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Zeiher AM. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute smyocardial infarction: final 1-year results of the REPAIR-AMI trial. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction.tion of mononuclear bone marrow cells in acute myocardial infarction. de WF. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Intracoronary autologous bone-marrow cell transfer after myocardial infarc-tion: the BOOST randomised controlled clinical trial. Asahara T, Losordo DW. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. outcome after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. In a recent article, Seeger et al. 1 compare …